Testing an inhaled lung medication for pulmonary fibrosis

This trial studied MNKD-201, an inhaled powder form of a medication called nintedanib, in people with idiopathic pulmonary fibrosis (IPF)—a condition where lung tissue becomes scarred and stiff. Researchers tested two different doses of the medication to see how safe it was, how well patients tolerated it, and how the body absorbed and processed it. Some participants received the active medication while others received a placebo (inactive powder) so researchers could fairly compare the results.

Idiopathic pulmonary fibrosis causes progressive scarring in the lungs, making it harder to breathe over time. This trial investigated whether delivering this medication directly to the lungs through inhalation—rather than by mouth—might be a more effective way to treat the disease and help patients breathe better.